For the Inventor, By the Inventor

Enter assignee name

Bengaluru, India

Aurigene Oncology Limited

USPTO Granted Patents = 19

EPO Patents = 5

Forward Citations = 14

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Muralidhara Ramachandra (10 out of 31 patents)

Pottayil Govindan Nair Sasikumar (7 out of 23 patents)

Seetharamaiah Setty Sudarshan Naremaddepalli (6 out of 19 patents)

4. Susanta Samajdar (6 out of 27 patents)

5. Chennakrishnareddy Gundala (3 out of 4 patents)

6. Chetan Pandit (2 out of 10 patents)

7. Subhendu Mukherjee (2 out of 11 patents)

8. Pottayil Govindan N Sasikumar (2 out of 7 patents)

9. Venkateshwar Rao Gummadi (2 out of 15 patents)

10. Leena Khare Satyam (2 out of 3 patents)

11. Suraj Tatyasaheb Gore (2 out of 2 patents)

12. Dinesh Chikkanna (1 out of 5 patents)

13. Girish Chandrappa Daginakatte (1 out of 3 patents)

14. Kiran Aithal Balkudru (1 out of 2 patents)

15. Brian R Hearn (1 out of 11 patents)

19 patents: Sort by Forward Citations

1. 12643870 - 1,2,4-oxadiazole derivatives as immunomodulators (2026-06-02),

2. 12570650 - 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders (2026-03-10),

3. 12565515 - 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways (2026-03-03),

4. 12428379 - Acylsulfonamide KAT6A inhibitors (2025-09-30),

5. 12410193 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2025-09-09),

6. 12377088 - Substituted tetrahydroquinolinone compounds as ROR gamma modulators (2025-08-05),

7. 12331023 - Substituted heterocyclyl derivatives as CDK inhibitors (2025-06-17),

8. 12290507 - Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors (2025-05-06),

9. 12268670 - Combination of small molecule CD-47 inhibitors with other anti-cancer agents (2025-04-08),

10. 12226402 - Dual inhibitors of TIM-3 and PD-1 pathways (2025-02-18),

11. 12187689 - Crystalline forms of 3-substituted 1,2,4-oxadiazole (2025-01-07),

12. 12064418 - Conjoint therapies for immunomodulation (2024-08-20),

13. 12037321 - 1,2,4-oxadiazole derivatives as immunomodulators (2024-07-16),

14. 12005045 - Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds (2024-06-11),

15. 11981685 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2024-05-14),

Company Overview

Aurigene Oncology Limited is a biotechnology company based in Bengaluru, India, specializing in the discovery and development of innovative cancer therapeutics. The organization focuses on harnessing advanced research in oncology to create targeted therapies that address unmet medical needs in cancer treatment. With a commitment to scientific excellence, Aurigene leverages its expertise in drug discovery and development to advance novel compounds through various stages of clinical evaluation, aiming to improve patient outcomes in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

19 Patents

#20 in Bengaluru

#102 in India

#32,663 in the World

Bengaluru, India

Aurigene Oncology Limited

Forward Citations = 14

37 inventors:

Muralidhara Ramachandra (10 out of 31 patents)

Pottayil Govindan Nair Sasikumar (7 out of 23 patents)

Seetharamaiah Setty Sudarshan Naremaddepalli (6 out of 19 patents)

4. Susanta Samajdar (6 out of 27 patents)

5. Chennakrishnareddy Gundala (3 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aurigene Oncology Limited. Retrieved from https://idiyas.com/company/aurigene-oncology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…